These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 8675970)

  • 1. A detailed longitudinal analysis on the use of naltrexone in the treatment of bulimia.
    Marrazzi MA; Kinzie J; Luby ED
    Int Clin Psychopharmacol; 1995 Sep; 10(3):173-6. PubMed ID: 8675970
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Binge eating disorder: response to naltrexone.
    Marrazzi MA; Markham KM; Kinzie J; Luby ED
    Int J Obes Relat Metab Disord; 1995 Feb; 19(2):143-5. PubMed ID: 7735342
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Naltrexone use in the treatment of anorexia nervosa and bulimia nervosa.
    Marrazzi MA; Bacon JP; Kinzie J; Luby ED
    Int Clin Psychopharmacol; 1995 Sep; 10(3):163-72. PubMed ID: 8675969
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Naltrexone improves blood glucose control in type 1 diabetic women with severe and chronic eating disorders.
    Raingeard I; Courtet P; Renard E; Bringer J
    Diabetes Care; 2004 Mar; 27(3):847-8. PubMed ID: 14988322
    [No Abstract]   [Full Text] [Related]  

  • 5. Treatment of antidepressant-resistant bulimia with naltrexone.
    Jonas JM; Gold MS
    Int J Psychiatry Med; 1986-1987; 16(4):305-9. PubMed ID: 3557806
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A placebo-controlled, double-blind crossover study of naltrexone hydrochloride in outpatients with normal weight bulimia.
    Mitchell JE; Christenson G; Jennings J; Huber M; Thomas B; Pomeroy C; Morley J
    J Clin Psychopharmacol; 1989 Apr; 9(2):94-7. PubMed ID: 2656781
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Opiate antagonists in children and adolescents.
    Chabane N; Leboyer M; Mouren-Simeoni MC
    Eur Child Adolesc Psychiatry; 2000; 9 Suppl 1():I44-50. PubMed ID: 11140779
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The use of opiate antagonists in treating bulimia: a study of low-dose versus high-dose naltrexone.
    Jonas JM; Gold MS
    Psychiatry Res; 1988 May; 24(2):195-9. PubMed ID: 2841709
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High-dose naltrexone and liver function safety.
    Marrazzi MA; Wroblewski JM; Kinzie J; Luby ED
    Am J Addict; 1997; 6(1):21-9. PubMed ID: 9097868
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Naltrexone and bulimic symptoms.
    Igoin-Apfelbaum L; Apfelbaum M
    Lancet; 1987 Nov; 2(8567):1087-8. PubMed ID: 2889994
    [No Abstract]   [Full Text] [Related]  

  • 11. Naltrexone treatment of bulimia: clinical and theoretical findings linking eating disorders and substance abuse.
    Jonas JM; Gold MS
    Adv Alcohol Subst Abuse; 1987; 7(1):29-37. PubMed ID: 2831700
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Naltrexone reverses bulimic symptoms.
    Jonas JM; Gold MS
    Lancet; 1986 Apr; 1(8484):807. PubMed ID: 2870306
    [No Abstract]   [Full Text] [Related]  

  • 13. Bulimia treated with imipramine: a placebo-controlled, double-blind study.
    Pope HG; Hudson JI; Jonas JM; Yurgelun-Todd D
    Am J Psychiatry; 1983 May; 140(5):554-8. PubMed ID: 6342421
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of a tricyclic antidepressant and opiate antagonist on binge-eating behavior in normoweight bulimic and obese, binge-eating subjects.
    Alger SA; Schwalberg MD; Bigaouette JM; Michalek AV; Howard LJ
    Am J Clin Nutr; 1991 Apr; 53(4):865-71. PubMed ID: 2008865
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Naltrexone in organic bulimia: a preliminary report.
    Childs A
    Brain Inj; 1987; 1(1):49-55. PubMed ID: 3454671
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of decreasing afferent vagal activity with ondansetron on symptoms of bulimia nervosa: a randomised, double-blind trial.
    Faris PL; Kim SW; Meller WH; Goodale RL; Oakman SA; Hofbauer RD; Marshall AM; Daughters RS; Banerjee-Stevens D; Eckert ED; Hartman BK
    Lancet; 2000 Mar; 355(9206):792-7. PubMed ID: 10711927
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of the opiate antagonist, naltrexone, on binging antecedents and plasma beta-endorphin concentrations.
    Chatoor I; Herman BH; Hartzler J
    J Am Acad Child Adolesc Psychiatry; 1994 Jun; 33(5):748-52. PubMed ID: 8056738
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Psychosocial and pharmacological treatment of eating disorders: a review of research findings.
    Peterson CB; Mitchell JE
    J Clin Psychol; 1999 Jun; 55(6):685-97. PubMed ID: 10445860
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of bulimia nervosa with topiramate in a randomized, double-blind, placebo-controlled trial, part 2: improvement in psychiatric measures.
    Hedges DW; Reimherr FW; Hoopes SP; Rosenthal NR; Kamin M; Karim R; Capece JA
    J Clin Psychiatry; 2003 Dec; 64(12):1449-54. PubMed ID: 14728106
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treating bulimia with desipramine. A double-blind, placebo-controlled study.
    Hughes PL; Wells LA; Cunningham CJ; Ilstrup DM
    Arch Gen Psychiatry; 1986 Feb; 43(2):182-6. PubMed ID: 3511878
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.